HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C, Spadazzi C, Ibrahim T, Pieri F, Foca F, Calabrese C, De Vita A, Miserocchi G, Cocchi C, Vanni S, Ercolani G, Cavaliere D, Ranallo N, Chiadini E, Prisinzano G, Severi S, Sansovini M, Martinelli G, Bongiovanni A, Mercatali L.
Liverani C, et al. Among authors: severi s.
Front Endocrinol (Lausanne). 2023 Jan 20;13:1045038. doi: 10.3389/fendo.2022.1045038. eCollection 2022.
Front Endocrinol (Lausanne). 2023.
PMID: 36743926
Free PMC article.